IRLAB A — IRLAB Therapeutics AB Share News
0.000.00%
Last trade - 00:00- SEK165.12m
- SEK155.10m
- SEK57.46m
Advisory: Multiple dated alerts withdrawn
Brief: IRLAB Strengthens Patent Protection For Phase IIb/III Drug Candidate Mesdopetam
Brief: IRLAB Therapeutics Q3 Operating Loss Widens To SEK 26.9 Mln
Brief: IRLAB's Mesdopetam IND Accepted By The US FDA
Brief: IRLAB Therapeutics Approved For Listing On Nasdaq Stockholm Main Market
Brief: Irlab Q2 Operating Loss Narrows To SEK 26.1 Mln
Brief: Irlab Therapeutics Says No Dividend Shall Be Paid For Past Financial Year
Brief: Irlab Q1 Operating Loss Widens To SEK 19.1 Mln
Brief: Irlab: Clinical Drug Candidate Mesdopetam Published In JPET
Brief: IRLAB Therapeutics Raises SEK 145 Mln Through Rights Issue
Brief: Irlab Therapeutics AB Q4 Operating Loss SEK 26.3 MLM
Brief: IRLAB Carried Out A Directed Issue Of Sek 70 Mln And Resolves On A Rights Issue Of About Sek 145 Mln
Brief: IRLAB Therapeutics Q3 Operating Loss Widens To SEK 21.5 Million
Brief: IRLAB Gets Patents In USA And Europe
Brief: Irlab Therapeutics Q2 Operating Loss Widens To SEK 30.4 Mln
Brief: IRLAB To Advance Clinical Development Of IRL790 In LIDs
Brief: Irlab Reports Top Line Results From Phase Iia Study With Irl790
Brief: IRLAB And Research Consortium Awarded SEK 2.9 Mln Vinnova Grant
Brief: IRLAB Therapeutics Announces Share Split